Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary. 2020

Dustin O'Neall, and Emese Juhász, and Ákos Tóth, and Edit Urbán, and Judit Szabó, and Szilvia Melegh, and Katalin Katona, and Katalin Kristóf
1 Diagnostic Laboratory of Clinical Microbiology, Institute of Laboratory Medicine, Semmelweis University, Budapest,Hungary.

Our objective was to compare the activity ceftazidime-avibactam (C/A) and ceftolozane-tazobactam (C/T) against multidrug (including carbapenem) resistant Pseudomonas aeruginosa clinical isolates collected from six diagnostic centers in Hungary and to reveal the genetic background of their carbapenem resistance. Two hundred and fifty consecutive, non-duplicate, carbapenem-resistant multidrug resistant (MDR) P. aeruginosa isolates were collected in 2017. Minimal inhibitory concentration values of ceftazidime, cefepime, piperacillin/tazobactam, C/A and C/T were determined by broth microdilution method and gradient diffusion test. Carbapenem inactivation method (CIM) test was performed on all isolates. Carbapenemase-encoding blaVIM, blaIMP, blaKPC, blaOXA-48-like and blaNDM genes were identified by multiplex PCR. Of the isolates tested, 33.6% and 32.4% showed resistance to C/A and C/T, respectively. According to the CIM test results, 26% of the isolates were classified as carbapenemase producers. The susceptibility of P. aeruginosa isolates to C/A and C/T without carbapenemase production was 89% and 91%, respectively. Of the CIM-positive isolates, 80% were positive for blaVIM and 11% for blaNDM. The prevalence of Verona integron-encoded metallo-beta-lactamase (VIM)-type carbapenemase was 20.8%. NDM was present in 2.8% of the isolates. Although the rate of carbapenemase-producing P. aeruginosa strains is high, a negative CIM result indicates that either C/A or C/T could be effective even if carbapenem resistance has been observed.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006814 Hungary A country in Europe, northwest of Romania, south of Slovakia, and east of Austria. The capital is Budapest.
D000078142 Tazobactam A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria. Tazobactam Sodium,YTR 830,YTR 830H,YTR-830,YTR830

Related Publications

Dustin O'Neall, and Emese Juhász, and Ákos Tóth, and Edit Urbán, and Judit Szabó, and Szilvia Melegh, and Katalin Katona, and Katalin Kristóf
January 2020, Access microbiology,
Dustin O'Neall, and Emese Juhász, and Ákos Tóth, and Edit Urbán, and Judit Szabó, and Szilvia Melegh, and Katalin Katona, and Katalin Kristóf
October 2019, Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia,
Dustin O'Neall, and Emese Juhász, and Ákos Tóth, and Edit Urbán, and Judit Szabó, and Szilvia Melegh, and Katalin Katona, and Katalin Kristóf
February 2018, Journal of clinical microbiology,
Dustin O'Neall, and Emese Juhász, and Ákos Tóth, and Edit Urbán, and Judit Szabó, and Szilvia Melegh, and Katalin Katona, and Katalin Kristóf
April 2023, Microbial drug resistance (Larchmont, N.Y.),
Dustin O'Neall, and Emese Juhász, and Ákos Tóth, and Edit Urbán, and Judit Szabó, and Szilvia Melegh, and Katalin Katona, and Katalin Kristóf
December 2017, Antimicrobial agents and chemotherapy,
Dustin O'Neall, and Emese Juhász, and Ákos Tóth, and Edit Urbán, and Judit Szabó, and Szilvia Melegh, and Katalin Katona, and Katalin Kristóf
May 2023, The new microbiologica,
Dustin O'Neall, and Emese Juhász, and Ákos Tóth, and Edit Urbán, and Judit Szabó, and Szilvia Melegh, and Katalin Katona, and Katalin Kristóf
September 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,
Dustin O'Neall, and Emese Juhász, and Ákos Tóth, and Edit Urbán, and Judit Szabó, and Szilvia Melegh, and Katalin Katona, and Katalin Kristóf
October 2022, Microbiology spectrum,
Dustin O'Neall, and Emese Juhász, and Ákos Tóth, and Edit Urbán, and Judit Szabó, and Szilvia Melegh, and Katalin Katona, and Katalin Kristóf
August 2023, Antimicrobial agents and chemotherapy,
Dustin O'Neall, and Emese Juhász, and Ákos Tóth, and Edit Urbán, and Judit Szabó, and Szilvia Melegh, and Katalin Katona, and Katalin Kristóf
September 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,
Copied contents to your clipboard!